TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06304571
Drug: HC006
Normalized name: Hydrocortisone
DrugBank: Hydrocortisone succinate (DB14545)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Specified dose on specified days
Study: NCT05364255
Drug: [14C]AZD9833 Oral Solution, 75 mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral Solution, 75 mg (NMT 0.67 MBq) - oral, fasted
Study: NCT05332795
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: gouty patients, will receive placebo tablets once daily for about 3 months.
Study: NCT05007444
Drug: P2Et (Caesalpinia spinosa extract)
Normalized name: Caesalpinia spinosa whole extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients who meet inclusion criteria will begin taking 4000mg daily, distributed in 2 doses with meals of 2000mg of P2Et extract during neoadjuvant treatment. In case of presenting toxicity, it will be lowered to the next dose level, that is, 2000 mg under the same dosage schedule and 1000 mg following the same principle. The taking of the phytomedicine will only be suspended 3 days before each cycle of standard neoadjuvant therapy and will restart 3 days after having passed the cycle. That is, in the anthracyclines and cyclophosphamide (AC) phase, the patient will start taking the phytomedicine 3 days after having received their standard chemotherapy cycle and will suspend it 3 days after the next cycle begins. For the taxane phase, the patient will take the P2Et without suspension during the treatment cycles.
Study: NCT05007444
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: After determining the optimal biological dose (OBD), the patients will be divided into the placebo arm or the treatment arm. In the anthracyclines and cyclophosphamide (AC) phase, the patient will start taking according to the asignation as stated in the drug intervention.
Study: NCT05099445
Drug: INCB000928
Approvals — FDA: no, EMA: no, PMDA: no
Description: INCB000928 200 mg will be administered on Day 1 of each treatment period.
Study: NCT05456503
Drug: FPI-2620
Approvals — FDA: no, EMA: no, PMDA: no
Description: Radiotracer
Study: NCT04983732
Drug: FL-101-Intravenous
Normalized name: OXT-101
Approvals — FDA: no, EMA: no, PMDA: no
Description: 150 mg administered via the IV route
Study: NCT04983732
Drug: FL-101-Subcutaneous
Normalized name: OXT-101
Approvals — FDA: no, EMA: no, PMDA: no
Description: 150 mg administered via the SC route
Study: NCT05864014
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo
Study: NCT06217146
Drug: Placebo Oil
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo Oil
Study: NCT04925934
Drug: VIB7734
Approvals — FDA: no, EMA: no, PMDA: no
Description: VIB7734
Study: NCT05821595
Drug: JYB1907
Approvals — FDA: no, EMA: no, PMDA: no
Description: for injection
Study: NCT04828525
Drug: normal saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo
Study: NCT05320588
Drug: BIO-106
Normalized name: Bio-Kool
Approvals — FDA: no, EMA: no, PMDA: no
Description: BIO-106 is a novel antibody-drug conjugate (ADC) that targets the human trophoblast cell surface antigen 2 (Trop-2)
Study: NCT05789342
Drug: Rosuvastatin
Normalized name: Rosuvastatin
DrugBank: Rosuvastatin (DB01098)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Rosuvastatin, tablet, oral
Study: NCT05099276
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Three capsules of cellulose given in post-anesthesia room and three capsules for postop cay one and three capsules for postop day two
Study: NCT05484167
Drug: Natesto Nasal Product
Normalized name: Natesto Nasal Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nasal Gel used for 90 days then crossed over to placebo gel
Study: NCT05484167
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: A nasal gel with no active ingredients
Study: NCT00232921
Drug: caudal volume 1
Normalized name: VOLUME EXPANDERS
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT06367114
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Cyclophosphamide is used for lymphodepletion.
Study: NCT06488001
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo given the night before surgery, 2 hours prior to surgery, and the evening after surgery.
Study: NCT05314725
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 days of placebo after surgery
Study: NCT05570422
Drug: KRC-01
Approvals — FDA: no, EMA: no, PMDA: no
Description: KRC-01 is a solution that contains hydrogen peroxide 3% with sodium hyaluronate 1%. Hydrogen peroxide is the active ingredient for this radiosensitizer.
Study: NCT04935515
Drug: Intravenous Antibiotics with Low dose steroid.
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous ceftriaxone with either oral methyl prednisolone or intravenous dexamethasone was given
Study: NCT00000987
Drug: Doxorubicin hydrochloride
Normalized name: Doxorubicin Hydrochloride
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT05673655
Drug: intraoral trigger point injection by botox
Normalized name: onabotulinumtoxinA Injection [Botox]
Approvals — FDA: no, EMA: no, PMDA: no
Description: intraoral injection of trigger point of masseter muscle by botulinum toxin
Study: NCT05673655
Drug: transcutaneous trigger point injection by botox
Normalized name: onabotulinumtoxinA Injection [Botox]
Approvals — FDA: no, EMA: no, PMDA: no
Description: transcutaneous injection of masseter muscle by botulinum toxin
Study: NCT05797077
Drug: Capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Maintenance therapy is recommended to be continued with low-toxicity drugs such as 5-FU/LV or capecitabine, and may be combined with targeted therapy. Treatment should be discontinued once ctDNA testing is negative.
Study: NCT05898373
Drug: vedicitumomab (Edisil, RC48）
Approvals — FDA: no, EMA: no, PMDA: no
Description: intravenously for 6-8 cycles before surgery and postoperative radiotherapy, followed by Treatment with injectable recombinant humanized anti-HER2 monoclonal antibody-MMAE coupling agent vedicitumomab (Edisil, RC48) until 1 year or disease progression or intolerable toxicity in locally advanced patients , and until disease progression or intolerable toxicity in metastatic patients .
Study: NCT06273930
Drug: 8% Arginine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Arginine contributes to Whole Mouth Health. It also plays a role with respect to dental caries, helping to maintain a pH-neutral environment, and is proven to rapidly help relieve dentin sensitivity. Arginine is truly a remarkable ingredient now being used in oral care products.
Study: NCT06591091
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Listed in arm/group description
Study: NCT06215586
Drug: Tovinontrine (CRD-750
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tablets administered orally
Study: NCT06215586
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tablets administered orally
Study: NCT05551221
Drug: Ningmitai capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ningmitai Capsule (Ningmitai®) is Traditional Chinese Medicine which has already used in treatment of urinary system disease (eg. CPPS, BPH) in China for more than twenty years. The instruction of Ningmitai Capsule is 0.38g/capsule, 4 capsule/time, tid.
Study: NCT01344200
Drug: Celecoxib
Normalized name: Celecoxib
DrugBank: Celecoxib (DB00482)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: In Phase I twenty (20) children will receive either celecoxib 14 or 7 mg/kg 120-180 minutes prior to lumbar puncture (LP). In Phase II forty-five (45) children will receive celecoxib 14 mg/kg, 7 mg/kg or placebo in one of 5 time intervals, 1-24 hours prior to LP.
Study: NCT01344200
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: In Phase II forty-five (45) children will receive celecoxib 14 mg/kg, 7 mg/kg or placebo in one of 5 time intervals, 1-24 hours prior to LP.
Study: NCT04964388
Drug: GLP-1 receptor agonist
Normalized name: GLP-1 receptor agonist
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diabetes medication
Study: NCT05396391
Drug: IAP0971
Approvals — FDA: no, EMA: no, PMDA: no
Description: IAP0971 should be subcutaneous injected，q2w
Study: NCT06512233
Drug: LMW Heparin 5000 U/ML-Aspirin 75 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Arm 1
Study: NCT06512233
Drug: LMW Heparin 5000 U/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Arm 2
Study: NCT05141747
Drug: MRG002
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administrated intravenously
Study: NCT06063343
Drug: KAND145
Approvals — FDA: no, EMA: no, PMDA: no
Description: In Part 1 of the study, single ascending doses of KAND145 will be administered; in Part 2 of the study, multiple ascending doses (BID for 8 days) of KAND145 will be administered.
Study: NCT06063343
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants randomized to the placebo arms will receive placebo at the same dosing frequency as the experimental arms.
Study: NCT06245707
Drug: prednisone,methylprednisone and cyclophosphamide
Approvals — FDA: no, EMA: no, PMDA: no
Description: In the first month, methylprednisolone 500mg/d was given intravenously for 3 days, and then prednisone 0.5 mg/(kg d) \* for 27 days. Oral cyclophosphamide 2.0 mg/(kg d) \* 30 days in the second month. After that, the first month and the second month plan were repeated twice.
Study: NCT05074147
Drug: Reduction in the duration of antibiotic therapy 3 weeks or 6 weeks
Normalized name: REDUCTIC ACID
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drugs :~* Rifampin (IP an PO) : 10mg/Kg/12h~* Ofloxacin (PO) : 200Mg/8h~* Levofloxacin (PO) : 500mg ot 1g/ twice a day~* Ciprofloxacin : IV : 400mg/8h if Pseud spp ; 400mg/12h for others Gram-negative bacilli strains; PO : 1gr/12h if Pseud spp ; 750mg/12h for others Gram-negative bacilli strains~* Clindamycin : 600-900mg/8h~* Fusidic Acid : 500mg/8h~* Teicoplanin : 10mg/kg/12h for 5 dosis in combination, then in monotherapy.~* Ceftasidim : 2g/8h if Pseud spp ; 2g/12h for others Gram-negative bacilli strains~* Trimethoprim-sulfamethoxazole (800mg/160mg) : once per day if patient \< 80Kg ; one and a half per day if patient \> 80Kg.~* Doxycyclin : 200mg/day~* Minocyclin : 100mg/8h to 12h~* Ceftriaxon : 1g to 2g/day in IV, IM or SC~* Cefotaxim : 1g to 2g/day in IV~* Pristinamycin : 1g thrice a day
Study: NCT05810623
Drug: Intravesical Solution
Normalized name: Rimso-50 Intravesical Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravesical single dose instillation of chemotherapy within 24h from uretero-renoscopy
Study: NCT04757584
Drug: Beta blockers
Normalized name: BETA BLOCKERS/RELATED
Approvals — FDA: no, EMA: no, PMDA: no
Description: The intervention is a two-arm crossover withdrawal/ reversal design (On \[A\] vs Off \[B\]) with up to 4 periods, each period lasting up to 6 weeks. During the On period (A), subjects will be on their beta blocker. During the Off period (B), their beta blockers will be down-titrated and subsequently discontinued.~Subjects will be randomized into either ABAB or BABA sequences.
Study: NCT06218550
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Consumption of a brownie or inhalation of ambient air through a cannabis vaporizer by health adult research volunteers
Study: NCT05595395
Drug: Enteral Dose Form
Normalized name: Product manufactured as enteral dose form
Approvals — FDA: no, EMA: no, PMDA: no
Description: In this intervention arm, fluid substitution is primarily done via enteral administration. The used substance for enteral fluid administered is going to be tap water. Intravenous fluid of choice is going to be Elomel isoton.
Study: NCT05595395
Drug: Intravenous Infusion
Normalized name: intravenous infusion pump accessory
Approvals — FDA: no, EMA: no, PMDA: no
Description: In this intervention arm, fluid substitution is primarily done via intravenous administration. The used substance for intravenous fluid administered is going to be Elomel isoton.
Study: NCT04837742
Drug: ESPB group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: ESPB injection at T10 region with Chirocaine 100mg(20 cc)+ Omnipaque 10cc
Study: NCT04837742
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: ESPB injection at T10 region with Normal saline 20cc + Omnipaque 10cc
Study: NCT05297760
Drug: Saline 0.9%
Normalized name: CVS Saline 0.9% Nasal Mist
Approvals — FDA: no, EMA: no, PMDA: no
Description: Physiological saline solution for use as vehicle for the biological drug (Polvac Grass+Rye) or as placebo.
Study: NCT04656431
Drug: Hyperpolarized pyruvate (13C)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Given intravenously (IV) injection prior to imaging
Study: NCT05125978
Drug: Canadá
Approvals — FDA: no, EMA: no, PMDA: no
Description: Canadá association 1 tablet twice a day
Study: NCT04798287
Drug: TNF Inhibitor
Normalized name: Tumor necrosis factor alpha (TNF-alpha) inhibitors
Approvals — FDA: no, EMA: no, PMDA: no
Description: First eligible prescription for treating rheumatoid arthritis (RA)
Study: NCT05895500
Drug: Tablet (50mg/tablet), oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tablet
Study: NCT05901961
Drug: Whitfield solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: The patient will receive 60 mL of Whitfield solution. They will be instructed to apply 0.5 mL of the solution to the lesion twice daily for a consecutive period of 8 weeks.
Study: NCT05901961
Drug: Zinc oxide nanoparticles solution
Normalized name: Zinc Oxide
DrugBank: Zinc oxide (DB09321)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: The patient will receive 60 mL of 1% Zinc oxide nanoparticles solution. They will be instructed to apply 0.5 mL of the solution to the lesion twice daily for a consecutive period of 8 weeks.
Study: NCT05901961
Drug: Combined Whitfield and Zinc oxide nanoparticles solution
Normalized name: Zinc Oxide
DrugBank: Zinc oxide (DB09321)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: The patient will receive 60 mL of combined Whitfield and Zinc oxide nanoparticles solution. They will be instructed to apply 0.5 mL of the solution to the lesion twice daily for a consecutive period of 8 weeks.
Study: NCT06028737
Drug: Leucovorin
Normalized name: Leucovorin
DrugBank: Leucovorin (DB00650)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 200 mg/m², d1, i.v., every 2 weeks
Study: NCT06028737
Drug: Fluorouracil
Normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 2600 mg/m²d1 i.v. every 2 weeks
Study: NCT06134414
Drug: MY008211A tablets
Approvals — FDA: no, EMA: no, PMDA: no
Description: dose 1 (400 mg BID) and dose 2 (600 mg BID) in a 1:1 ratio by central randomization
Study: NCT04937530
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo Comparator: Placebo Inactive comparator capsule 960 mg/capsule: 3 capsules TID for 4 weeks, followed by 3 capsules BID for the remaining 44 weeks.
Study: NCT04987970
Drug: D013, D326, D337
Approvals — FDA: no, EMA: no, PMDA: no
Description: QD, PO
Study: NCT05082155
Drug: Normal Saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: Normal saline will be delivered as a basal infusion of 1 mL/h and an automatic intermittent bolus of 20 mL every 4 hours.
Study: NCT05406895
Drug: 2% Lidocaine with 1:100,000 epinephrine
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2% Lidocaine with 1:100,000 epinephrine will be used for administering the lower jaw anesthesia (inferior alveolar nerve block).
Study: NCT06193629
Drug: Lang Qingata
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lang Qingata: (Artificial bezoar: 0.1g, Safflower: 15g, five spirit fat: 15g, Tangerine: 30g, Swertia: 15g, nutmeg: 10g, Astragalus: 25g, wood fragrance: 10g, Parasol tiger grass: 15g, Coriander fruit: 10g, Agarwood: 3g, pomegranate seed: 20g, Rhododendron: 8g, Dongquai fruit: 15g, licorice: 10g). Water decoction (hospital decoction), Decoction in water for oral use，2 times/day, 4 weeks for a course of treatment.
Study: NCT06193629
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo is a Chinese medicine granule with 5% active ingredient and has the same taste as Lang Qingata，Decoction in water for oral use
Study: NCT00629213
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT04608851
Drug: E. coli Nissle
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 ml of oral suspension containing 10 E8 CFU /ml of E. coli Nissle strain
Study: NCT06364540
Drug: Fentanyl
Normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Nebulized fentanyl administered at 3 mcg/kg via BAN
Study: NCT05697692
Drug: Heparin sodium
Normalized name: Heparin Sodium
DrugBank: Heparin (DB01109)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Lung transplantation on central veno-arterial ECMO with standard additional heparin
Study: NCT05697692
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lung transplantation on central veno-arterial ECMO without additional heparin
Study: NCT04808895
Drug: Acetylsalicylic acid
Normalized name: ACETYLSALICYLIC ACID
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: administration of one tablet daily for 15 days. On the first day a loading dose of 300 mg will be administered
Study: NCT04808895
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: administration of one tablet daily for 15 days. On the first day 3 tablets will be administered
Study: NCT04773977
Drug: IBI362 liquid formulation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered by subcutaneous injection
Study: NCT04773977
Drug: IBI362 lyophilized powder
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered by subcutaneous injection
Study: NCT05187832
Drug: AND019 PO QD
Approvals — FDA: no, EMA: no, PMDA: no
Description: AND019 administrated as oral capsule once per day for 28 days for each cycle
Study: NCT05420454
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 600 mg/m2, d1, q3w ,4 cycles,followed by docetaxel
Study: NCT05420454
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 600 mg/m2, d1, q2w × 4 cycles followed by nab-paclitaxel
Study: NCT06235541
Drug: GENA-104A16
Approvals — FDA: no, EMA: no, PMDA: no
Description: GENA-104A16 is administered as a 1 hour (h) \[-5 minutes and +60 minutes , i.e., 55-120 minutes as window time\] as intravenous (IV) infusion on q2w.
Study: NCT05673850
Drug: NET or NCT
Normalized name: Medicated Pad or Tape
Approvals — FDA: no, EMA: no, PMDA: no
Description: In this study, we included 518 ER-positive BC patients who received either neoadjuvant endo-crine therapy (NET) or neoadjuvant chemotherapy (NCT).
Study: NCT05937282
Drug: normal saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients will receive infusion of 25 ml normal saline in 50ml syringe pump (control group).
Study: NCT05206331
Drug: Iodinated Contrast Media (ICM)
Normalized name: Stellaria media extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: standard FDA-approved low osmolarity Iodine contrast agent with 350-370 mg/ml
Study: NCT04889651
Drug: BR9004
Approvals — FDA: no, EMA: no, PMDA: no
Description: BR9004: Abiraterone acetate 200mg, Boryung Pharmaceutical Co., Ltd.
Study: NCT04889651
Drug: BR9004-1
Approvals — FDA: no, EMA: no, PMDA: no
Description: BR9004-1: Zytiga Tab. 500mg (Abiraterone acetate 500mg), Janssen Korea
Study: NCT06358677
Drug: Topical Tretinoin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical tretinoin will be applied to one half of the face, either left or right side. The side the topical tretinoin will be applied to will be randomized.
Study: NCT06401616
Drug: OAC will be discontinued for the duration of the trial
Approvals — FDA: no, EMA: no, PMDA: no
Description: Discontinuation of warfarin, dabigatran, rivaroxaban, apixaban or edoxaban
Study: NCT04895215
Drug: AB-2004
Normalized name: Crotalidae immune F(ab')2 Injection [Anavip]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Taken 3 times daily with food
Study: NCT04895215
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Take 3 times daily with food
Study: NCT05481645
Drug: TQB2450 injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: TQB2450 is a humanized monoclonal antibody targeting programmed death ligand-1 (PD-L1), which prevents the binding of PD-L1 to PD-1 and B7.1 receptors on the surface of T cells, thereby reactivating T cells and enhancing the immune response.
Study: NCT05481645
Drug: Doxorubicin Hydrochloride Injection
Normalized name: Doxorubicin Hydrochloride Injection
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Doxorubicin hydrochloride is a cycle non-specific anticancer chemotherapy drug, which directly acts on DNA, changes the nature of DNA template, and inhibits DNA polymerase.
Study: NCT05520177
Drug: 601 1.25mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: loading phase (6 months): 601 1.25mg/eye/time, Intravitreal injection, administered once every 4 weeks for 6 consecutive doses
Study: NCT05937100
Drug: Biodentine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Molars will be anesthetized by local anesthesia. The rubber dam will be used for isolation. Caries will be removed by large spoon excavator. When pulpal exposure occurs, deroofing of the pulp chamber will be achieved then pulpal tissue will be amputated using sharp excavator. Hemostasis will be obtained by applying pressure with saline moist cotton pellet. If bleeding has not stopped within 5 min, tooth will be excluded from the study.The biodentine mix will be prepared according to the manufacturer's instructions and condensed lightly with a condenser on the pulp stumps
Study: NCT05552495
Drug: D013, D326, D337
Approvals — FDA: no, EMA: no, PMDA: no
Description: D013 1 Tablet, D326 1Tablet, D337 1 Tablet
Study: NCT05525715
Drug: 2mg QY201 tablets or 2mg QY201 placebo,BID
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2mg QY201 tablets or 2mg QY201 placebo,BID
Study: NCT05525715
Drug: 5mg QY201 tablets or 5mg QY201 placebo,BID
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5mg QY201 tablets or 5mg QY201 placebo,BID
Study: NCT05525715
Drug: 10mg QY201 tablets or 10mg QY201 placebo,QD
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10mg QY201 tablets or 10mg QY201 placebo,QD
Study: NCT05525715
Drug: 10mg QY201 tablets or 10mg QY201 placebo,BID
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10mg QY201 tablets or 10mg QY201 placebo,BID
Study: NCT05525715
Drug: 15mg QY201 tablets or 15mg QY201 placebo,BID
Approvals — FDA: no, EMA: no, PMDA: no
Description: 15mg QY201 tablets or 15mg QY201 placebo,BID
Study: NCT05525715
Drug: 20mg QY201 tablets or 20mg QY201 placebo,BID
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20mg QY201 tablets or 20mg QY201 placebo,BID
Study: NCT05525715
Drug: 5mg QY201 tablets，BID
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5mg QY201 tablets，BID
Study: NCT05525715
Drug: 10mg QY201 tablets，BID
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10mg QY201 tablets，BID